top of page
Thechnology & Pre-clinical Recearch
Technology:
ShortCut™ Catheter
ShortCut
Unmet Needs in Current TAVI World
01
02
Degenerated valves that require reintervention present a risk of coronary obstruction and coronary access impairment
TAVI in native valves present a risk of coronary impairment in a select group of patients
ShortCut™ Catheter
First dedicated transcatheter leaflet splitting device
Intended to enable coronary access and prevent coronary obstruction during TAVI
Complete control over positioning and leaflet splitting location
Designed for safe, simple splitting of single or double leaflets, with short procedural times
The ShortCut™ Procedure
Play Video
CAUTION Investigational device. Limited by Federal law to Investigational Use. The ShortCut™ device is to be used exclusively for clinical investigations.
Pi-Cardia owns multiple issued patents and pending patent applications in multiple jurisdictions around the world that cover or relate to various aspects of the technology embedded in the ShortCut™. US Patent 11,690,637
bottom of page